Efficacy of Low-Dose Aripiprazole for Treatment of Psychotic Symptoms in a Patient with 22q11.2 Deletion Syndrome (OPEN ACCESS)

Name: Efficacy of Low-Dose Aripiprazole for Treatment of Psychotic Symptoms in a Patient with 22q11.2 Deletion Syndrome (OPEN ACCESS)
SKU: 23362
Availability: InStock

$0.00

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Categories: Open Access Articles, VOL 50 No. 1 Articles 2020 Tags: 22q11 deletion syndrome, aripiprazole, Charalambos C. Papageorgiou, Eleni Lazaratou, Konstantina G. Yiannopoulou, Konstantinos Kontoangelos, Marina Economou, psychopharmacology, psychosis, velocardiofacial syndrome

Description

Description

Complicated Case History

Efficacy of Low-Dose Aripiprazole for Treatment of Psychotic Symptoms in a Patient with 22q11.2 Deletion Syndrome

By Konstantinos Kontoangelos, Eleni Lazaratou, Marina Economou, Konstantina G. Yiannopoulou, Charalambos C. Papageorgiou

Efficacy of Low-Dose Aripiprazole for Treatment of Psychotic Symptoms in a Patient with 22q11.2 Deletion Syndrome (OPEN ACCESS)

Description

Complicated Case History

Philip T. Ninan, MD: Generalized Anxiety Disorder: Diagnosis, Neurobiology, and Treatment

Branimir Margetic: A Case of Stuttering During Treatment with Levomepromazine

Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil

C. Lindsay DeVane, PharmD: An Explanation of the Second-Dose Effect in Pharmacokinetics and Its Meaning for Clinical Psychopharmacology

Efficacy of Low-Dose Aripiprazole for Treatment of Psychotic Symptoms in a Patient with 22q11.2 Deletion Syndrome (OPEN ACCESS)

Description

Complicated Case History

Related products

Philip T. Ninan, MD: Generalized Anxiety Disorder: Diagnosis, Neurobiology, and Treatment

Branimir Margetic: A Case of Stuttering During Treatment with Levomepromazine

Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil

C. Lindsay DeVane, PharmD: An Explanation of the Second-Dose Effect in Pharmacokinetics and Its Meaning for Clinical Psychopharmacology